

Datasheet for ABIN7647722

anti-TNFRSF13C antibody



Overview

| Quantity: | 100 μL |
|--------------|--------------------------------------------------------------------------------------------------------|
| Target: | TNFRSF13C |
| Reactivity: | Mouse |
| Host: | Rabbit |
| Clonality: | Polyclonal |
| Conjugate: | This TNFRSF13C antibody is un-conjugated |
| Application: | Western Blotting (WB), Immunohistochemistry (IHC), Immunocytochemistry (ICC), Immunoprecipitation (IP) |

Product Details

| Product Details | |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Purpose: | Polyclonal Antibody to B-Cell Activation Factor Receptor (BAFFR) |
| Immunogen: | RPA281Mu01Recombinant BCell Activation Factor Receptor (BAFFR) |
| Isotype: | IgG |
| Specificity: | The antibody is a rabbit polyclonal antibody raised against BAFFR. It has been selected for its ability to recognize BAFFR in immunohistochemical staining and western blotting. |
| Cross-Reactivity: | Rat |
| Purification: | Antigen-specific affinity chromatography followed by Protein A affinity chromatography |
| Target Details | |
| Target: | TNFRSF13C |

Target Details

| Alternative Name: | BAFFR (TNFRSF13C Products) |
|---------------------|---------------------------------------------------------------------------------------------------------|
| Background: | CD268, TNFRSF13C, TNFRSF13-C, BAFF-R, BAFFR, BR3, Tumor Necrosis Factor Receptor Superfamily Member 13C |
| UniProt: | Q9D8D0 |
| Pathways: | NF-kappaB Signaling |
| Application Dataile | |

Application Details

| Application Notes: | Western blotting: 0.01-2 μ g/mL,Immunohistochemistry: 5-20 μ g/mL,Immunocytochemistry: 5-20 μ g/mL,Immun |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | 20 μg/mL,Optimal working dilutions must be determined by end user. |
| Comment: | The thermal stability is described by the loss rate. The loss rate was determined by accelerated |
| | thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious |
| | degradation and precipitation were observed. The loss rate is less than 5% within the expiration |
| | date under appropriate storage condition. |
| Restrictions: | For Research Use only |

Handling

| Format: | Liquid |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Concentration: | 0.5 mg/mL |
| Buffer: | 0.01M PBS, pH 7.4, containing 0.05 % Proclin-300, 50 % glycerol. |
| Preservative: | ProClin, Sodium azide |
| Precaution of Use: | This product contains ProClin and Sodium azide: POISONOUS AND HAZARDOUS SUBSTANCES which should be handled by trained staff only. |
| Storage: | 4 °C,-20 °C |
| Storage Comment: | Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles. |